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Abstract: Background and objectives: Glial brain cancers affect nearly 20,000 individuals in the
United States (USA) annually. SEER database data exploring the relationship between race and
gliomas is now available and have shown that cerebral gliomas occur at a higher frequency in
Caucasian men. However, such analyses did not include demographic data specific to the state of
Florida. This study assessed the association between race and glial vs. non-glial Central Nervous
System (CNS) cancers in Florida, USA. Materials and Methods: This case-control study utilized the
Florida Cancer Data Registry (FCDS), in which race was considered the exposure and development
of glioma as the measured outcome. The sample was comprised of patients in Florida diagnosed with
brain tumors from 1981 to 2013. Relative racial frequencies were compared between patients with
glial brain tumors and those with other CNS tumors. Data was analyzed using logistic regression in
order to determine any associations between race and frequency of diagnosis adjusting for several
confounders (age, sex, smoking status, year of diagnosis, and insurance status). Results: Between 1981
and 2013 a total of 14,092 patients meeting the inclusion and exclusion criteria were diagnosed in
Florida with a primary brain tumor. Being of non-white race was associated with 60% decreased odds
of glioma diagnosis compared to the reference white population (adjusted OR 0.4, 95% CI 0.34–0.47).
Secondary findings include associations between increasing age and male sex with increased odds of
glioma diagnosis. Decreased adjusted odds of glioma diagnosis were found with former smoking
status (reference non-smokers), diagnosis between 2001 and 2010 (reference 1981–1990), and Medicaid
or Medicare insurance (reference private insurance). Hispanic ethnicity, current smoking status,
no insurance/self-pay, and geographical location (urban vs. rural) all had no association with glioma
diagnosis. Conclusions: These findings are consistent with and help reinforce previous studies utilizing
national databases (SEER) which also showed increasing odds of glioma diagnosis in older white
males. Various potential explanations for these findings include genetic predisposition, lifestyle and
behavioral factors, and socioeconomic status, including access to healthcare. Future research aims at
identifying potential genetic etiologies.
Keywords: glioma; brain cancer; race; populations; Florida; demographics
1. Introduction
Cancers of the brain affect more than 20,000 American families annually [1]. Among those
affected, nearly 10,000 cases are gliomas [2]. Cancers of glial origin, or gliomas, arise from glia,
the supporting cells of the brain. These cells give rise to more than 80% of all primary brain
malignancies [3]. Among the most common types of brain cancers, these tumors may be further
classified as astrocytomas, arising from astrocytes, oligodendrogliomas, from oligodendrocytes,
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and ependymomas from ependymal cells [4]. There are several hypotheses proposing models for
the development of gliomas [5]. The most commonly accepted of these echoes the Knudson two-hit
hypothesis [6]. This theory proposes that genetic changes, whether inherited or environmental,
alter critical genes affecting the regulatory capacity of cells. When both copies of such genes are
affected, unchecked proliferation of glial cells gives way to the formation of gliomas. Though this
pathway has not been proven in gliomas, several critical genetic mutations have been identified [7].
In 2017, the classification system for the diagnosis of gliomas was revised to include these
biochemical changes in addition to cell type, location, and grade [4,8]. Among many changes are the
addition of isocitrate dehydrogenase (IDH) mutation status, 1p/19q deletion status, ATP-dependent
helicase (ATRX) function, p53 mutation, and nitric oxide synthase (NOS) status [9]. As the
understanding of the role of these mutations in the pathogenesis of glioma increases, and as we
prepare ourselves to further direct treatment based on genetic and epigenetic changes, it is more
important than ever that scientists and clinicians aim for timely diagnosis and treatment of glial
cancers [9].
Despite advances in the diagnosis and treatment of these cancers, they are notoriously aggressive,
invasive, and destructive [10]. Of the 10,000 cases of malignant gliomas diagnosed in the United States,
only 25% survive one year after their diagnosis [3]. The mean survival time of only 9 to 12 months has
remained stable despite intensity of treatment. The high morbidity and mortality associated with the
diagnosis of glioma is largely due to the lack of a uniform approach to treatment [5]. Treatment is often
complicated by molecular phenotypic variation necessitating a multi-modal treatment approach [11].
This is further complicated by the heterogeneous anatomy of these tumors. Often, advanced tumors
may lie in proximity to the hypothalamus, requiring an exquisitely delicate surgical approach [12].
Comprehensive therapy often entails surgery, radiotherapy, and chemotherapy [7].
The overall incidence of cancers of the brain has increased over the last thirty years but has recently
begun a gradual decline [3]. Despite this statistic, the incidence of glioblastoma is increasing [3].
National data on the diagnosis of glial cancers is maintained by the National Cancer Data System.
This data generated a robust analysis of demographic associations with frequency of diagnosis of
glioma relative to non-glial brain cancers from 1997 to 2007. This study demonstrated that the frequency
of gliomas is highest in white Americans, with lower rates in blacks, and the least frequent in East
and Southeast Asians [1]. Further, this analysis revealed that men were more frequently diagnosed
than women, and that elderly individuals were more likely to be diagnosed than younger adults [1].
Those residing in more metropolitan communities were more likely to be diagnosed than those in rural
areas [1].
It is proposed that these associations may not necessarily reflect a purely biological attribution [5].
With increased use of computerized tomography (CT), the incidence of cancers of the brain skyrocketed
in the 1970s [3]. Further, the demographic most likely to have access to CT scans likely correlates well
with the data [5]. This is to say that older white men in metropolitan areas are more likely than other
subgroups to be diagnosed with glial cancers and yet may not necessarily represent a difference in
biological association, but rather missed opportunities for diagnosis in other populations [5].
The aim of our study is to investigate the association between race and the type of brain cancer
(gliomas vs. non-glial brain cancers) in the state of Florida from 1981 to 2016. In achieving this
objective, it is the larger goal of the authors to generate meaningful data to support clinical screening
and treatment [12,13].
2. Materials and Methods
For this study, we conducted a case–control study utilizing publicly available data from the
Florida Cancer Dataset [14]. In the database, glioma tumor data was available using the ICD codes
C710–719 from their earliest recording through 31 December 2016.
The population of interest was patients diagnosed with brain tumors in the state of Florida.
This population was divided into patients who developed “gliomas”, and our comparator group,
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those who developed “non-glioma CNS tumors”. This classification was based on the following
ICD-03 codes: Gliomas: C710–C19 with morphology codes 9380, 9400, 9410, 9411, 9420, 9450, 9460,
9451; Non-Gliomas: 9440, 9441, 9442. The control group consisted of all patients from Florida with
non-glial primary brain tumor diagnoses available in FCDS. They were unmatched, as the potential
confounders did not allow proper cross-matching with the glioma group. Exclusion criteria included
duplicate records, data from patients less than 18 years old at diagnosis, and records with a missing or
“unknown” race value.
The dependent variable in this study is the type of brain tumor, classified in two groups: patients
with glioma brain tumors and patients with non-glioma brain tumors. The independent variable
is the racial status, which was aggregated as white or non-white. The FCDS database utilized the
2000 Census and Bureau of Vital Statistics to encode the race variable with respondents self-reporting
their race. The FCDS database fields NAACCR 160, 161, 162, 163, 164 correspond to the following
racial groups: white, black, other, and unknown. Thus “white” consisted of the “white” group and
non-white included “black” and “other”, with all data records with a value of “unknown” excluded
per criteria. Potential confounders included age, gender, Hispanic ethnicity, smoking status, year of
diagnosis, insurance status, and geographic region (urban or rural).
Data were analyzed using STATA version 14. Measurements of central tendency and dispersion
were reported for continuous variables. Absolute and relative frequencies were reported for categorical
variables. Each instance of a cancer diagnosis was characterized by the patient’s racial category.
For both glial and non-glial cancers, the frequency of glioma tumors for each racial group, as well as
the frequency of non-glioma CNS tumors were calculated. We further subdivided our cases and control
groups to analyze relative frequency of diagnosis between races based upon age, gender, Hispanic
ethnicity, smoking status, year of diagnosis, insurance status, and geographic region, defined by the
Rural Health Research Center [7]. Chi squared test (for categorical variables) and Student’s t-test
(for continuous variables) were used to assess associations between variables of interest and race.
A logistic regression model was utilized to compute unadjusted and adjusted odd ratios (OR) and
corresponding 95% confidence intervals (CI). Variables found to be associated with the independent
and dependent variables were deemed potential confounders and included in the adjusted model.
An alpha level of 0.05 or lower was used to assess statistical significance.
The FCDS database is a publicly available, de-identified database maintained by the Florida
Department of Health in conjunction with the University of Miami Sylvester Comprehensive Cancer
Center. Access and use of FCDS data were obtained via agreement with the Florida International
University Herbert Wertheim College of Medicine and signed certificates of confidentiality. As the
data was de-identified and retrospective, this study was classified as non-human subject research and
thus exempt from requiring IRB approval.
3. Results
Figure 1 shows the process for selecting the patients included in the study. Between 1982 and
2013 a total of 17,936 patients were diagnosed in Florida with a primary brain tumor. After applying
the selection criteria, 14,092 patients were retained for the study. Information regarding patients’
characteristics is summarized in Table 1. Mean age at diagnosis of a glioma was older in white patients
(55.9 years) as compared to non-whites (48.5 years) (p ≤ 0.001). There were also significant differences
between races in the distributions of smoking status, Hispanic ethnicity, year of diagnosis, insurance
status, and geographical region (p ≤ 0.001). On the contrary, there was no significant difference with
respect to sex between white and non-white individuals (p = 0.128).
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Figure 1. Development of sample population of Floridians diagnosed with gliomas and non-glial 
primary CNS tumors from 1981 to 2013 based on inclusion and exclusion criteria. 
Table 1. Characteristics of the study participants by race in USA from 1981 to 2013. 
Characteristics Race p-Value 
 Caucasian African-American  
 N (%) N (%)  
Age 1 (Years)—Mean (SD 2) 55.9 (18.2) 48.5 (16.8) ≤0.001 
Gender   0.128 
Male 6793 (53.5) 715 (51.4)  
Female 5902 (46.5) 677 (48.6)  
Hispanic Ethnicity    
Hispanic 1777 (14.1) 68 (5.0)  
Non-Hispanic 10791 (85.9) 1306 (95.1)  
Smoking Status   ≤0.001 
Never Smoker 5716 (58.4) 726 (68.2)  
Current Smoker 1966 (20.1) 199 (18.7)  
Former Smoker 2113 (21.6) 140 (13.2)  
Year of Diagnosis   ≤0.001 
1981–1990 3037 (23.9) 175 (12.6)  
1991–2000 3788 (29.8) 383 (27.5)  
2001–2010 4771 (37.6) 672 (48.3)  
2011–2013 1104 (8.7) 162 (11.6)  
Insurance Status   ≤0.001 
Not Insured/Self Pay 575 (7.3) 755 (14.8  
Medicare 2803 (35.6) 255 (24.4)  
Medicaid 613 (7.8) 183 (17.5)  
Other Public Insurance 193 (2.5) 22 (2.1)  
Private Insurance 3684 (42.8) 431 (41.2)  
Region   ≤0.001 
Urban 11,450 (94.3) 1312 (96.0)  
Rural 692 (5.7) 55 (4)  
1 Age analysis using t-test, all other variables Chi Squared analysis; 2 Standard deviation. 
Figure 1. Development of sample population of Floridians diagnosed with gliomas and non-glial
primary CNS tumors from 1981 to 2013 based on inclusion and exclusion criteria.
Table 1. Characteristics of the study participants by race in USA from 1981 to 2013.
Characteristics R ce p-Value
Caucasian African-American
N (%) N (%)
Age 1 (Years)—Mean (SD 2) 55.9 (18.2) 48.5 (16.8) ≤0.001
Gender 0.128
Male 6793 53.5) 715 (51.4)
Female 5902 (46.5) 677 (48.6)
Hispanic Ethnicity
Hispanic 1777 (14.1) 68 (5.0)
Non-Hispanic 10791 (85.9) 1306 (95.1)
Smoking Status ≤0.001
Never Smoker 5716 (58.4) 726 (68.2)
Current Smoker 1966 (20.1) 199 (18.7)
Former Smoker 2113 (21.6) 140 (13.2)
Year of Diagnosis ≤0.001
1981–1990 3037 (23.9) 175 (12.6)
1991–2000 3788 (29.8) 383 (27.5)
2001–2010 4771 (37.6) 672 (48.3)
2011–2013 1104 (8.7) 162 (11.6)
Insurance Status ≤0.001
Not Insured/Self Pay 575 (7.3) 755 (14.8
Medicare 2803 (35.6) 255 (24.4)
Medicaid 613 7.8) 183 (17.5)
Other Public Insurance 193 (2.5) 22 (2.1)
Private Insurance 3684 (42.8) 431 (41.2)
Region ≤0.001
Urban 11,450 (94.3) 1312 (96.0)
Rural 692 (5.7) 55 (4)
1 Age analysis using t-test, all other variables Chi Squared analysis; 2 Standard deviation.
As detailed in Table 2, there was a significant difference in racial frequency according to the type of
brain tumor (glioma vs non-glioma) (p ≤ 0.001). Additionally, the two groups also showed statistically
significant differences according to age, sex, smoking status, year of diagnosis, and insurance status
(p ≤ 0.001). There were no statistically significant diffe nces by geographical reg (p = 0.196) or
Hispanic ethnicity (p = 0.996).
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Table 2. Population characteristics according to diagnosis of glioma versus non-glial CNS tumors in
USA from 1981 to 2013.
Characteristics Type of CNS 1 Tumor p-Value
Non-Glioma Glioma
N (%) N (%)
Race ≤0.001
Caucasian 3255 (25.6) 9445 (74.4)
African-American 606 (43.5) 786 (56.5)
Age 2 (Years)—Mean (SD 3) 59.6 (17.7) 53.5 (18.1) ≤0.001
Gender ≤0.001
Male 1810 (24.1) 5698 (75.9)
Female 2047 (31.1) 4532 (68.9)
Hispanic Ethnicity 0.886
Hispanic 509 (27.6) 1336 (72.4)
Non-Hispanic 3318 (27.4) 8779 (72.6)
Smoking Status ≤0.001
Never Smoker 1739 (27.0) 4703 (73.0)
Current Smoker 515 (23.8) 1650 (76.2)
Former Smoker 684 (30.4) 1569 (69.6)
Year of Diagnosis ≤0.001
1981–1990 397 (12.4) 2815 (87.6)
1991–2000 951 (22.8) 3220 (77.2)
2001–2010 2172 (39.9) 3271 (60.1)
2011–2013 341 (26.9) 925 (73.1)
Insurance Status ≤0.001
Not Insured/Self Pay 199 (27.3) 531 (72.7)
Medicare 1349 (44.1) 179 (55.9)
Medicaid 268 (33.7) 528 (66.3)
Other Public Insurance 56 (26.1) 159 (74.0)
Private Insurance 1115 (27.1) 3000 (72.9)
Region 0.196
Urban 3585 (28.1) 9177 (71.9)
Rural 204 (27.3) 542 (72.7)
1 Central Nervous System; 2 Age analysis using T-test, all other variables Chi Squared analysis; 3 Standard Deviation.
Table 3 shows the unadjusted and adjusted associations between the different demographic
characteristics and the diagnosis of glioma versus non-glial CNS tumor. Several of the independent
variables studied were significantly associated with the type of CNS tumor. The adjusted odds of
having a glioma is 60% less in non-whites compared with whites (55% less using unadjusted model).
After adjustment for the covariates the odds of being diagnosed with glioma decreases by 3% with each
year of advancing age (95% CI 0.97–0.98). Further, the adjusted odds of having a glioma is 27% less in
females compared to males. The adjusted odds of glioma diagnosis is the same in current smokers
as compared with those who have never smoked; however, former smokers had a 14% decreased
odds of being diagnosed with glioma. Additionally, the odds of glioma diagnosis from 2001–2010
decreased by 68% (95% CI 0.14–0.72) relative to 1981–1990. Odds of glioma diagnoses were similar
between 1991–2000 and 2011–2013 relative to the reference of the 1981–1990 decade. Those insured
by Medicare and Medicaid were 20% (95% CI 0.70–0.93) and 29% (95% CI 0.58–0.86) less likely to be
diagnosed with glioma than those with private insurance, respectively. After adjusting to exclude
insurance status, the only change in significance occurred in the year of diagnosis, altering the OR to
0.47 (95% CI 0.40–0.55) from 1991–2000 and 0.39 (0.32–0.48) between 2011 and 2013. There were no
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significant associations between Hispanic ethnicity, current smoking status, and the geographic region
with tumor type.
Table 3. Unadjusted and adjusted associations between population characteristics and odds of diagnosis
of glioma and non-glial CNS tumors.
Characteristics Unadjusted Adjusted p-Value Adjusted withoutInsurance p-Value
OR 1 (95% CI 2) OR (95% CI) OR (95% CI)
Race
Caucasian Reference Reference Reference
African American 0.45 (0.4–0.5) 0.40 (0.34–0.47) ≤0.001 0.42 (0.36–0.48) ≤0.001
Age 0.98 (0.98–0.98) 0.97 (0.97–0.98) ≤0.001 0.98 (0.97–0.98) ≤0.001
Sex
Male Reference Reference Reference
Female 0.70 (0.65–0.76) 0.73 (0.65–0.81) ≤0.001 0.81 (0.74–0.90) ≤0.001
Hispanic
Non-Hispanic Reference Reference Reference
Hispanic 0.99 (0.89–1.10) 0.90 (0.77–1.06) 0.197 0.81 (0.71–0.92) 0.002
Smoking Status
Never Smoker Reference Reference Reference
Current Smoker 1.18 (1.06–1.33) 1.00 (0.86–1.16) 0.956 0.93 (0.82–1.05) 0.235
Former Smoker 0.85 (0.76–0.94) 0.86 (0.76–0.99) 0.031 0.88 (0.79–0.99) 0.034
Year of Diagnosis
1981–1990 Reference Reference Reference
1991–2000 0.48 (0.42–0.54) 0.67 (0.30–1.53) 0.346 0.47 (0.40–0.55) ≤0.001
2001–2010 0.21 (0.19–0.24) 0.32 (0.14–0.72) 0.006 0.22 (0.19–0.26) ≤0.001
2011–2013 0.38 (0.33–0.45) 0.57 (0.25–1.29) 0.176 0.39 (0.32–0.48) ≤0.001
Insurance Status
Not Insured/Self
Pay 0.99 (0.83–1.18) 0.92 (0.74–1.14) 0.460 -
Medicare 0.47 (0.43–0.52) 0.80 (0.70–0.93) 0.004 -
Medicaid 0.73 (0.62–0.86) 0.71 (0.58–0.86) 0.001 -
Other Public
Insurance 1.06 (0.77–1.44) 1.14 (0.78–1.67) 0.505 -
Private Insurance Reference Reference Reference
Region
Urban Reference Reference Reference
Rural 1.04 (0.88–1.23) 0.96 (0.77–1.20) 0.713 1.02 (0.84–1.25) 0.821
1 Odds Ratio; 2 Confidence Interval.
4. Discussion
Our investigation regarding the relationship between diagnosis of the type of CNS tumors and
race in Florida uncovered a significant increase in glioma diagnosis in the white population compared
with the non-white population. This effect was demonstrated even after controlling for the potential
confounders of age, sex, smoking status, year of diagnosis, and insurance status. Other factors such as
age, sex, and insurance status were also independently associated with significant difference in glioma
cancer rates; however, none had as large an effect as race.
Our findings are consistent with previously published data by Ostrom et al. and Dubrow et al. [1,3],
which both demonstrated increased odds of glioma diagnosis in whites when compared to non-whites.
This is to say, the demonstration of older white men as the demographic most frequently diagnosed
with glial cancers in Florida is consistent with current literature. Unfortunately, given the paucity of
studies with comprehensive data sources, we are unable to place some of the secondary findings
between insurance status and glioma, and year of diagnosis and glioma into the broader context of
scientific literature.
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There are numerous potential underlying explanations for the racial effect this study uncovered.
It is hypothesized that these differences may be attributable to underlying genetic differences or to
the social determinants of health [13]. Multiple genes have been associated with the development of
gliomas and further research may demonstrate a propensity of these mutations in white Americans
compared to non-white Americans [4]. Regarding the latter, it is well substantiated that non-white
Americans are frequently under-diagnosed due to lack of access to health services [13].
Another possible rationale for this finding may include socioeconomic status and lack of access
to healthcare, an endemic public health challenge affecting non-white communities across the
United States. Additionally, the state of Florida is predominantly categorized as “white” by the
US Census, with 2017 estimates that 77% of the population identifies as “white” [13]. This fact,
compounded with racial differences in access, could contribute to the racial effect. This health inequity
is perpetuated by several underlying factors, including historical trauma resulting in avoidance of
medical professionals, cost barriers, and generalized impaired access to care [15,16]. These factors
could cause those of low socioeconomic status, who tend disproportionately to be racial minorities,
to be underdiagnosed and undercounted in the FCDS database. Further support for the impact of
socioeconomic status is garnered from the analysis of insurance status. The analysis of collected data
supports this by showing that those with private insurance are more likely to be diagnosed with a
glioma compared to those covered by Medicaid and Medicare. Explanations for the delayed age of
diagnosis are non-specific, though the molecular development of cancers center on the accumulation
of genetic mutations that necessitates an element of time and could play a role. The underlying
causes of glioma are poorly understood, including the observed relationship with cigarette smoking.
Though several associated genes have been identified, including survival and proliferation factors,
investigation in this field may generate valuable information in the identification and treatment of
those affected by gliomas [16]. It is hypothesized that analysis of other behavioral and genetic features
may reveal valuable clinical and biological information in the identification and treatment of glial
cancers. Further studies should attempt to link genetic factors with glioma development and diagnosis.
Numerous large-scale cohort studies with whole-genome sequencing data are being developed for
various investigations and could prove an invaluable tool in uncovering genetic markers associated
with glioma development.
Secondary findings from this investigation include significant associations between increased age,
male gender, former smoking status, diagnosis from 2001 to 2010, and being insured by Medicare or
Medicaid with higher rates of glioma. The significant findings between age and glioma status echo
similar results among many other types of cancer, where greater age allows an increased number of
genetic mutations that may ultimately lead to cancer. Several different lifestyle choices may contribute
to the development of gliomas, including smoking habits. It is somewhat counterintuitive that former
smoking status significantly decreased the odds of glioma; however, given the 95% CI interval upper
range is 0.99, it is not outside the realm of possibility that this finding is explained by random or
sampling variation. The fact that no relationship was found with current smoking status further
diminishes the strength of this association. Additionally, smoking status is traditionally associated
with increased and not decreased rates of cancer. This finding is disputed by two cohort studies
published by Holick et al., 2007, which concluded that there is strong evidence that cigarette smoking
is not associated with an increased risk of adult gliomas [17]. A more recent survey of literature by
Shao et al., 2016, further supported this conclusion by an investigative method of a dose-response
meta-analysis of case-control and cohort studies of cigarette smoking and glioma [18].
From the general survey of available data, neither the geographical region of a patient’s
residence, nor being of Hispanic ethnicity were associated with any specific type of CNS tumor.
This finding was of particular interest since our hypothesis investigated race as an independent
variable, and both geographical region and Hispanic ethnicity have similar relationships to race.
For example, many regions are racially dominated by primarily one race with relatively few areas
of heterogeneous populations. The lack of these associations generated a corollary exploration to
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investigate the relationship of geographical location in Florida with glioma diagnosis. In doing so,
all zip codes in Florida were divided into regions of population density based upon Version 2.0 of the
Rural-Urban Commuting Areas (RUCA) developed in conjunction with the University of Washington
and the US Office of Rural Health Policy (ORHP) [19]. This is an interesting note because the criteria
for a rural area classification included isolated, small rural, and large rural areas. Thus, while one
can inquire about possible environmental exposures or hazards that could potentially trigger genetic
alterations leading to glioma development by mechanisms similar to the Knudson-two hit hypothesis
or by means of primary development, this investigation was unable to definitively answer these
questions [5].
Naturally, this study has some limitations. The FCDS dataset utilized for this investigation did
not have data regarding alcohol use or socioeconomic status, limiting the model’s ability to account
for these potential confounders. While the study had a large population that met both the selection
criteria, various subgroup analyses were not possible given the small numbers of participants with
those characteristics. For example, while there was more data regarding race available, the small
numbers of non-whites (Hmong, Thai, Laotian, Pakistani, etc.) necessitated grouping. On the other
hand, the large number of glioma cancers found in the FCDS data set, despite their relative rarity,
provide robust power and offer compelling evidence of a real effect. Lastly, the study was limited
by the quality of the FCDS with inter-observer pathology variability likely having a minimal, but
unmeasurable impact.
5. Conclusions
This analysis serves to reflect the work of the surveillance and reporting efforts for institutions
throughout the state of Florida. Our study effectively describes the racial demographic most likely
to be diagnosed with having gliomas in Florida, which is data that was previously unpublished.
Beyond demography, we are able to construct a complete picture of the individuals most frequently
diagnosed based on the analysis of multiple factors, including geography, smoking status, insurance
status, gender, and age. By understanding this data, we may more effectively target individuals for
screening. Further, this analysis assists in the identification of populations that may be underdiagnosed
with tumors of glial origin.
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